A New Breed Of Accelerators Helps Drive Digital Health

Many digital health start-ups require more than just capital to navigate the complicated waters of the health care industry, and a new group of seed accelerators has emerged to help meet their needs. Medtech Insight interviews Healthbox director Ateet Adhikari.

If recent investment trends are an accurate barometer, digital health care (including wireless devices and software and information technology solutions) has emerged as the new darling of early-stage health care investors. There are now a growing number of high-tech digital solutions under development to address everything from provider cost and efficiency issues to patient home-monitoring needs. The field is different than other health care segments, however, because many of the young companies seeking to enter this space are technology focused, and the principals may have little or no experience in the health care arena. As a result, these companies often require a depth of support that goes beyond what they might receive from traditional venture capital (VC) and angel funding sources. To address these needs, a new group of incubators has cropped up, known as digital health accelerators. Focused solely on the digital health technology space, these organizations fund and nurture start-up companies with promising health care technology solutions that need help navigating the complexities of the health care industry and its long list of rules, regulations, and traditions that can frustrate and hinder a young company unfamiliar with the territory.

Although health industry accelerators have been around for a while, the incubators specifically focused on digital health are bringing fresh...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

FDA’s AI Tool Won’t Make Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Stealth Mode AI Imaging Startup Faction Imaging Raises $10M

 

Faction Imaging has come out of stealth mode following six years of research and development studying medical imaging workflows in India, Japan and the US.

Medtronic Announces Collaboration To Create A ‘New Era’ in Surgical Training

 

Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By 

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

More from North America

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By 

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?